BIAF Stock Analysis: Buy, Sell, or Hold?
BIAF - bioAffinity Technologies, Inc. Common Stock
$0.84
0.03 (4.10%)
▲
5d:
-38.45%
30d:
-47.95%
90d:
-82.17%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When BIAF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BIAF is down 38.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BIAF is down 38.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BIAF is currently trading at $0.84, which is considered oversold relative to its 30-day fair value range of $1.22 to $1.85.
Technical Outlook: Technically, BIAF is showing sideways momentum. Immediate support is located at $0.78, while resistance sits at $1.67. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+611.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BIAF is showing sideways momentum. Immediate support is located at $0.78, while resistance sits at $1.67. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+611.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.22 -
$1.85
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 611.6% below Wall St target ($6.00)
- WARNING: Recommendation downgraded due to -38.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.22 -
$1.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.78
Resistance Level
$1.67
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.10
Wall Street Target
$6.00
(+611.6%)
Revenue Growth (YoY)
-27.1%
Profit Margin
-280.6%
Share & Embed Analysis
Last updated: June 24, 2026 6:21 AM ET
Data refreshes hourly during market hours. Next update: 7:21 AM
Data refreshes hourly during market hours. Next update: 7:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIAF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 59 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 52 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 63 BUY |
